Etelcalcetide Found to Increase Bone Mineral Density in SHPT
Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment.
Nephrology Conferences
Ankle-Brachial Index Predicts Vascular Calcification in SHPT
Analyses demonstrated that an ABI of 1.79 correlated with radiographic evidence of calcified vessels.
Epoetin Dose Linked With CVD, Mortality in Hemodialysis
Epoetin dose is significantly associated with cardiovascular disease whether patients had lower or higher hemoglobin levels, study finds.
IV Iron Therapy in CKD Increases Infection Risk
In a study, IV iron was associated with twice the risk for infections in CKD.
Thrice-Weekly Calcimimetic Dosing Feasible for SHPT
In a study, patients receiving cinacalcet under supervision 3 times per week after dialysis rather than after daily self-administration showed improvement in their parathyroid hormone levels.
Etelcalcetide Beneficial in Severe SHPT Uncontrolled With Cinacalcet
In a study, patients with uncontrolled SHPT were switched from oral cinacalcet to intravenous etelcalcetide.
Predictors of SHPT Progression in CKD Identified
Loss of renal function may not be the sole factor in SHPT development, according to new study findings.
Kidney Failure in the Elderly Linked to Low Serum Uromodulin
In a study of 933 individuals with a mean age of 78 years, higher serum uromodulin was associated with a lower risk of end-stage renal disease.
Nephrotic Syndrome Found to Raise Ischemic Stroke Risk
Taiwan study reveals a 38% increased risk of ischemic stroke among patients with nephrotic syndrome.
High Uric Acid Raises Death Risk in CKD
Patients with chronic kidney disease who have hyperuricemia have a 3-fold higher risk of all-cause mortality.
Next post in Kidney Week 2018
